Majority Of Medical Oncologists And Ob-Gyns Disagree With New Mammogram Recommendations, New Infogroup’s ORC Oncology Report Indicates
Recent recommendations by the US Preventive Task Force on Breast Cancer advising that women under the age of 50 should not get routine mammograms have resulted in fierce debate within the medical community. According to a new oncology study from ORC, an Infogroup Company, 70 percent of oncologists and 60 percent of ob-gyns disagree with the assertion that women should not get mammograms before the age of 50. The prevailing argument against the Task Force’s mammogram recommendation is that too many women under the age of 50 have breast cancer and that it would allow many breast cancer cases to go undetected.
ORC’s Oncology Report delved into research analysis on three important Oncology issues: assessing the impact of revised NSCLC staging, genetically linked breast cancer and PARP-1 Inhibitors and Reactions to New Mammogram Recommendations. The mammogram debate was one of a number of key issues covered in ORC’s study, which captured the awareness, perceptions, ideal patient profiles and adoption rates of physicians towards PARP-1 Inhibitors post FDA-approval as a treatment for breast and ovarian cancers. PARP-1 Inhibitors have been widely discussed and exhibit efficacy in clinical trials, but minimal data has been collected so far to gauge their wider acceptance. Fifty percent of medical oncologists and 80 percent of ob-gyns were unable to name any PARP-1 inhibitor without being prompted.
“We were initially concerned with the physician’s lack of awareness and information on PARP-1 Inhibitors, since such awareness can help determine therapy and answer important questions about genetically linked breast and ovarian cancer treatment,” said Vaibhav Varkhedkar, Vice President of ORC’s Oncology Practice . “However, based on our data, we are optimistic that the usage of PARP-1 Inhibitors post FDA-approval will grow and eventually become the treatment of choice for certain hard to treat breast and ovarian cancers.”
To learn more and to obtain a copy of the full report, visit http://lp.infogroup.com/oncology-report.About our Global Oncology Practice As a dedicated practice within our pharmaceutical business unit, ORC’s oncology team is a well recognized and respected provider of market research solutions spanning a myriad of complex issues in cancer diagnostics and treatment. All of our oncology-based research is anchored in our extensive knowledge of latest cancer epidemiology, disease modalities and marketing implications.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV